SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-18-000037
Filing Date
2018-02-12
Accepted
2018-02-12 16:42:13
Documents
8
Period of Report
2018-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cti_-x8xkxexchangexagreement.htm 8-K 58073
2 EXHIBIT 1.1 ctibiopharma-underwritinga.htm EX-1.1 323142
3 EXHIBIT 3.1 finalcti_-xcertificatexofx.htm EX-3.1 116560
4 EXHIBIT 4.1 specimencertificate.htm EX-4.1 16361
5 EXHIBIT 5.1 finalcti_-xommx5x1xopinion.htm EX-5.1 9182
6 EXHIBIT 10.1 finalcti_-xexchangexagreem.htm EX-10.1 74417
7 specimencertificate001.jpg GRAPHIC 304154
8 specimencertificate002.jpg GRAPHIC 137204
  Complete submission text file 0000891293-18-000037.txt   1207381
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 18597089
SIC: 2834 Pharmaceutical Preparations